Washington, D.C. – The Medical Imaging & Technology Alliance (MITA), the leading organization and collective voice of medical imaging and radiopharmaceutical manufacturers, innovators, and product developers, today offered the following comment in response to the Centers for Medicare and Medicaid Services (CMS) final Hospital Outpatient Prospective Payment System (HOPPS) rule:

“Despite a significant response to the solicitation from CMS for comments on OPPS Packaging Policy for diagnostic radiopharmaceuticals, the final rule does nothing to expand access to innovative and advanced imaging which use diagnostic radiopharmaceuticals. MITA will continue to engage the Administration and Congress to ensure Americans have access to these critical scans. MITA has been encouraged by Congress’ interest in the topic and the solution which most stakeholders have united around, the FIND Act (H.R.1199/S.1544) and stand ready to work with policy makers who want to provide the most accurate diagnosis to patients and providers.”

Molecular Imaging Homepage